|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
| |
|
|
|
|
|
|
|
|
Crucell & DSM strengthen & expand development of PER.C6 Protein & Monoclonal Antibody Licensing Business
|
|
Dow Corning
: 20 December, 2005 (New Product) |
|
|
Dutch biotechnology company Crucell N.V. and DSM Biologics, a Pharmaceutical Products' business unit of Royal DSM NV announced today that they will strengthen and expand the development of the PER.C6 protein and monoclonal antibody business. The two companies will create an integrated solution for production of recombinant proteins and monoclonal antibodies on PER.C6 in order to increase licensing and royalty income and accelerate the development and role out of the PER.C6 technology platform in the market. |
|
Dutch biotechnology company Crucell N.V. and DSM Biologics, a Pharmaceutical Products' business unit of Royal DSM NV announced today that they will strengthen and expand the development of the PER.C6 protein and monoclonal antibody business. The two companies will create an integrated solution for production of recombinant proteins and monoclonal antibodies on PER.C6 in order to increase licensing and royalty income and accelerate the development and role out of the PER.C6 technology platform in the market.
Crucell and DSM will develop and offer a fully integrated PER.C6 protein and monoclonal antibody production package for licensees to provide a true turn-key solution for protein and monoclonal antibody production. The system will include optimized clone generation technology, tailored media, batch, fed-batch and perfusion fermentation processes, fermentation equipment design, scale-up and scale-down solutions and regulatory support. The partnership's Research and Development to create this new platform will be based around a new joint R&D center, located in the Netherlands and the US East Coast.
The parties will expand their business development, marketing and customer services activities in the US and Europe. In addition, to accelerate role out of the PER.C6 technology platform in the market and establish PER.C6 as the platform of choice for the industry, the parties will implement a new strategy of partnering with other players with protein capability to develop and offer services for PER.C6, and provide flexibility for PER.C6 licensees to select their service provider.
Based on the progress made and milestones achieved with PER.C6 to date and an extensive evaluation of the market, DSM has selected the PER.C6 protein and monoclonal antibody licensing business with Crucell as one of its focal points for intensified innovation in its new strategy, Vision 2010. Following this strategy re-orientation DSM Biologics will concentrate its contract manufacturing activities in Groningen the Netherlands, which will be developed to support licensees of the PER.C6 technology.
'The protein market is growing rapidly and may reach USD 200 billion in 15 to 20 years, and we believe that PER.C6 has the potential to become the production platform of choice for an attractive part of that market,' said Leendert Staal, President of DSM. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
